Furthermore, PD-1/PD-L1 blockade is an established therapeutic approach for human melanoma, with some anti-PD-1 antibodies (pembrolizumab, nivolumab, cemiplimab) and anti-PD-L1 antibodies (atezolizumab, durvalumab, avelumab) approved by the FDA, which demonstrates their ability to induce remission of the disease [47]. Here, CD274 is linked to melanoma.